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This study was performed to clarify the role of soluble Fas (sFas) in lupus nephritis (LN) and establish a potential relationship
between LN and the −670 polymorphism of Fas in 67 patients with systemic lupus erythematosus (SLE), including a subset of
24 LN patients with proteinuria. Additionally, a group of 54 healthy subjects (HS) was included. The allelic frequency of the
−670 polymorphism of Fas was determined using PCR-RFLP analysis, and sFas levels were assessed by ELISA. Additionally, the
WT-1 protein level in urine was measured. The Fas receptor was determined in biopsies by immunohistochemistry (IHC) and in
situ hybridization (FISH) and apoptotic features by TUNEL. Results. The −670 Fas polymorphism showed that the G allele was
associated with increased SLE susceptibility, with an odds ratio (OR) of 1.86. The sFas was significantly higher in LN patients with
the G/G genotype, and this subgroup exhibited correlations between the sFas level and proteinuria and increased urinary WT-
1 levels. LN group shows increased expression of Fas and apoptotic features. In conclusion, our results indicate that the G allele
of the −670 polymorphism of Fas is associated with genetic susceptibility in SLE patients with elevated levels of sFas in LN with
proteinuria.
1. Introduction
Systemic lupus erythematosus (SLE) is a systemic autoim-
mune disease characterized by the production of autoanti-
bodies and multiorgan involvement, including kidney dam-
age in 60% of patients [1, 2]. Antinuclear antibodies (ANAs)
are the hallmark of SLE, and specific anti-Sm, anti-dsDNA,
anti-nucleosome, anti-C1q, and anti-GBM antibodies have
been associated with LN [3–5].
Renal involvement is a serious complication of SLE
because it can lead to high rates of morbidity and mortality
[6]. The diagnosis of glomerulonephritis is suspected when
proteinuria and urinary sediment alteration are accompanied
by arterial hypertension. These data may predict kidney
involvement, although renal biopsy remains the gold stan-
dard for the diagnosis and classification of LN. In particular,
histological analysis can be used to identify the lesion and
progression stages of renal disease according to the activity
and chronicity index. However, despite the benefits of renal
biopsy, this is an invasive procedure that requires an exhaus-
tive review by a skilled pathologist; therefore, alternative
biomarkers to identify renal disease are urgently needed [7].
Currently and traditionally used urinary biomarkers include
proteinuria >0.5 g/L, alterations in renal ultrasound results,
and changes in the rate of glomerular filtration, indicating
the degree of renal function. Recently, additional urinary
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biomarkers have been used to predict renal damage, includ-
ing markers of urinary podocytes, such as the transcription
factor Wilm’s tumor 1 (WT-1) [8].
Genetic susceptibility to SLE involves certainmajor histo-
compatibility complex class II (MHC II) alleles, such as HLA-
DRB1∗0301 and DRB1∗1501 [9]. In addition, polymorphisms
in genes encoding the cytokines interleukin-10 (IL-10), IL-
6, tumor necrosis factor-𝛼 (TNF-𝛼), and interferon-𝛾 (IFN-
𝛾) have been associated with SLE. Therefore, these poly-
morphisms could confer different degrees of susceptibility
according the ethnic group [10–12]. Additionally, mutations
in cytokine receptors and costimulatory molecules, such as
CD28/B7 [13], and polymorphisms in genes associated with
apoptosis, such as Fas, FasL, and Bcl-2, have been implicated
in disease pathogenesis [14]. Accordingly, SLE is a polygenic
disease in which different genes may be associated with
different SLE disease subsets, including the nephritogenic
phenotype.
Polymorphisms in the GMCP-1 gene were previously
shown to be associated with increased susceptibility to SLE
in a Mexican mestizo population [15, 16]. Additionally, the
−1149 G/T polymorphism of the prolactin promoter has been
correlated with the production of anti-DNA antibodies [17].
In contrast, the −653 G/A NRF-2 (erythroid nuclear factor-
2) polymorphism does not increase SLE susceptibility during
childhood, although such polymorphisms may be associated
with LN [18].
The role of apoptosis in SLE has been intensively studied,
and the Fas/CD95/Apo-1 gene has been mapped to the 10q
24.1 region.This gene consists of nine exons and eight introns
as well as the promoter responsible for allelic variations
in Fas, which can also modify the transcriptional rate. For
example, if a guanine (G) is replaced by an adenine (A)
at position −670, the resulting polymorphism increases the
binding affinity of the transcription factor STAT-1 for the
interferon gamma-activated sequence (GAS), which in turn
alters the transcription rate of the Fas receptor [19]. Another
polymorphism of Fas at position 297, with the presence
of a C allele, is associated with SLE development in the
Japanese population; interestingly, this polymorphism does
not increase the risk for SLE in the Italian population
[20].
TheFas receptor exists in two forms; one form is anchored
to the plasma membrane, whereas the other is soluble (sFas).
The latter form is highly regulated at the transcriptional
level [21, 22]. sFas plays a role as an antiapoptotic molecule
that blocks FasL or sFasL binding, and its concentration
in the serum of healthy subjects is independent of gen-
der and age [23]. Additionally, in clinical practice, sFas
has been defined as a marker of inflammation related to
endothelial dysfunction in chronic renal diseases [24–26]. In
SLE, sFas levels are increased due to a deletion in exon 6
[21, 23, 27], although knowledge about its participation in LN
is lacking.
The present study was performed to assess the pos-
sible role of the −670 Fas polymorphism in LN and
address the issue of whether increased levels of sFas are
related to podocyte damage, proteinuria, and autoantibody
production.
2. Materials and Methods
2.1. Biological Samples. This cross-sectional study of cases
and controls analyzed the −670 polymorphism of Fas in a
mestizo group of SLE patients living in the north-central
region of Mexico. The mean age of the subjects was 41.2 ±
22.1 years, and all patients met the American College of
Rheumatology (ACR) criteria for SLE classification [28]
(females 79.6% and males 20.3%).
The SLE group was divided into two subsets. This first
group lacked evidence of renal involvement, tested positive
forANAs (80%) or anti-dsDNAantibodies (Crithidia luciliae)
(7.14%), and showed negative or irrelevant levels of protein-
uria (mean level of 0.116 g/L). The second group had LN with
proteinuria levels higher than 0.5 g/L and displayed a positive
ANA test result (90%) and a high prevalence of anti-dsDNA
antibodies (67%). Additionally, a control group was included,
consisting of 54 healthy subjects (HS) without evidence of
autoimmune disease. This group was 84.31% female and
15.6% male with an average age of 34.3 ± 14.51 years, and
all HS tested negative for ANAs, anti-dsDNA antibodies,
and proteinuria. This study was performed according to the
principles of the Declaration of Helsinki and was approved
by the ethics committees of our institutions. After providing
detailed information, signed informed consent was obtained
from the patients and controls.
2.2. BloodCollection. Peripheral bloodwas collected inVacu-
tainer 7.2mg K2 EDTA tubes and used for DNA extraction;
simultaneously, tubes without anticoagulant were used to
obtain serum.
2.3. Autoantibodies. ANAmeasurements were performed by
immunofluorescence (IF) using HEp-2 cells and anti-DNA
antibodies by Crithidia luciliae (Immuno Concepts NA, Ltd.,
Sacramento, CA). The following antibody specificities were
quantified by enzyme-linked immunosorbent assay (ELISA):
anti-Ro-60 (EA 1595-9601 G), anti-La-48 (EA 1597-9601
G), anti-nRNP/Sm (EA 1591-9601 G), and antiglomerular
basement membrane (GBM) (EA 1251-9601 G), according to
the manufacturer’s recommendations (Euroimmun US Inc.).
2.4. Soluble Fas. sFas levels were determined using a com-
mercial ELISA kit (Quantikine Human sFAS/TNFRSF6 R&D
System, Abingdon, UK), and the optical density (OD) was
measured at 450 nm using an ELISA plate reader (Multiskan
FC,Thermo Scientific).The sFas concentrationwas expressed
in 𝜌g/mL according to the curves obtained from the stan-
dards.
2.5. Restriction Fragment Length Polymorphism (PCR-RFLP)
Analysis. The −670 polymorphism of the Fas receptor was
analyzed using PCR-RFLP analysis, as previously reported
[19]. DNA from peripheral blood was extracted usingMiller’s
modified technique [29]. The PCR reaction was performed
using Taq DNA polymerase (Platinum High Fidelity from
Invitrogen, Life Technologies) as follows. First, 1𝜇g of DNA
was placed in an Eppendorf tube with a reaction mixture
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containing 0.2mM of the sense (5󸀠-CTACCTAAGAGCTA-
TCTACCGTTC-3󸀠) and antisense (5󸀠-GGCTGTCCATG-
TTGTTGGCTGC-3󸀠) oligonucleotides; then, 5𝜇L of 10X
high fidelity PCR buffer, 25𝜇L of 2X nucleotides, 2 𝜇L of
50mM MgSO
4
, and 0.2 𝜇L of Taq enzyme mixture were
incubated at 4∘C and adjusted to a final volume of 50𝜇L with
H
2
O (GIBCO Ultrapure). The PCR reaction was performed
in aPerkinElmer 2400 thermocycler using 35 cycles at the fol-
lowing conditions: 94∘C for 2min, 94∘C for 30 s, 58∘C for 30 s,
and 72∘C for 30 s. A final reaction extension was performed
at 72∘C for 10min. PCR products were digested at 37∘C for 1 h
with the restriction enzymeMva-I (Cat. number 11288075001,
Roche Diagnostics, Indianapolis, USA), and 10 𝜇L of digested
and undigested PCR products was separately run in a 2%
agarose gels using 1X TAE buffer for 40min at 80 volts; the
gels were then stained with ethidium bromide. ADNA ladder
was used (1 Kb Plus DNA Ladder of Invitrogen), and the
gels were analyzed using the Carestream Molecular Imaging
Software, version 5.0.
2.6. Fas Expression Was Determined in
Renal Biopsies by Immunohistochemistry (IHC)
and by In Situ Hybridization (FISH)
2.6.1. Preparation of Fas Fluorescent Probes. Fluorescent-
labelled PCR-derived probes were synthesized by PCR using
a random-primed 𝜆gt11-human spleen library as a template
(Clontech, Palo Alto, CA, USA), using the following oligonu-
cleotides: Fas forward 5󸀠-GGT GGG TTA CAC TGG TTT
ACA-3󸀠 and backward 5󸀠-GTG CTA CTC CTA ACT GTG
AC-3󸀠 [30]. The PCR reaction was done by incubation of
1 𝜇g of template with 25 𝜇M of nucleotides 2X dNTP, 100 𝜇M
fluoro-Red-labelled-UTP (Amersham Biosciences, Bucking-
ham, UK), and 0.2 𝜇M of the aforementioned primers mixed
with 0.5U/50𝜇L of DNA polymerase (Platinum Taq DNA
polymerase High Fidelity of Invitrogen Life Technology Ltd,
Carlsbad, CA USA). The reaction tubes containing 50 𝜇L
of the sample mixture were amplified in a thermocycler
(PerkinElmer, GeneAmp PCR system 2400) using 30 cycles
(94∘C for 2min, 48∘C for 2min, and 72∘C for 1.4min). At
the end of the PCR, the amplificates were electrophoresed in
0.8% agarose.The internal fluorescent red labeling of the PCR
products was observed under ultraviolet light as reed bands
in agarose gels lacking in ethidium bromide.
2.6.2. In Situ Hybridization. Slides containing 4 𝜇m sections
of renal tissues were incubated with 0.02M HCl, permeabi-
lized with 0.01% Triton X-100/PBS-DEPC, and washed in
cold 20% acetic acid. Probes were adjusted to 50 ng/mL in
1 : 1 hybridization buffer: formamide and were applied indi-
vidually to the tissues. Tissues were prehybridized at 90∘C for
3min, followed by hybridization at 37∘C for 24 hrs, and were
washed in SSC 2X buffer. In addition, following the washes
some slides were counterstained with 4󸀠,6-Diamidine-2󸀠-
phenylindole dihydrochloride (DAPI) [31]. Finally, the slides
weremounted and evaluated under confocalmicroscope.The
intensity of the color red obtained by FISH was analyzed in
the software Image-Pro Plus Versión 7.0. (Media Cybernetics,
USA).
2.7. Biopsies. Tissues were from patients with LN and control
biopsies obtained during necropsy of individuals who died
in a car accident, after obtaining written consent from their
families. In all the patients, kidney biopsies were performed
percutaneously, and a segment of each biopsy was stained
for hematoxylin and eosin (H and E) and evaluated under
lightmicroscopy.Thebiopsies were classified according to the
ISN/RPS 2004 classification of LN [32].
2.8. Immunohistochemistry. The Fas receptor was detected
by IHC on 4 𝜇m thick sections of renal tissues mounted
on microscope slides. The specimens were dewaxed, perme-
abilized with 0.01% Triton X-100/phosphate buffered saline
(PBS), and then washed thrice with PBS. Endogenous per-





in methanol. After an additional wash, the tissues were incu-
bated for 12 hours with a monoclonal anti-APO-1 (DAKO)
and diluted 1 : 100 in 10% FBS-PBS, the tissues were then
washed in several changes of PBS, and the bound antibodies
were identified with HRP-goat anti-mouse IgG (Zymed,
Laboratories Inc., San Francisco, CA).The color reaction was





Louis, MO), and the reaction was stopped with 0.5M sulfuric
acid.The slideswere then examined under a lightmicroscope.
The assays were performed in triplicate and evaluated by
two pathologists in a blinded fashion. The intensity of the
color reaction obtained by IHC was analyzed in the software
Image-Pro Plus Versión 7.0. (Media Cybernetics, USA).
2.9. Other Parameters. Proteinuria was measured using the
conventional dry chemistry method. The level of the WT-1
podocyte marker was measured by ELISA in urine collected
over a 24 h period using a previously described method
[8]. Apoptotic features were detected by TUNEL (Roche
Molecular Biochemical’s. Penzberg, Germany).
2.10. Statistical Analysis. Differences in themeasured param-
eters between different groups were evaluated by analysis of
variance (ANOVA) tests with Tukey’s and Pearson’s correla-
tions. GraphPad Prism version 17 was used for analysis, and
𝑃 values < 0.05 were considered significant.
3. Results
3.1. The −670 Fas Polymorphism in SLE. After the PCR reac-
tion, the products were digested to obtain the polymorphic
fragments. The A/A genotype was identified as a 232-base
pair (bp) band, the G/G genotype appeared as a 188 bp band,
and the heterozygous A/G variant appeared as a doublet of
the 188 bp and 232 bp bands, as shown in Figure 1. The A and
G allelic frequencies were 0.41 and 0.45, respectively. These
results indicated that the Fas G allele was associated with
susceptibility to SLE,with odds ratios (ORs) of 1.86 (𝑃 = 0.03)
and 2.23 (𝑃 = 0.05) for the dominant and recessive models,
respectively (Table 1).
3.2. Soluble Fas Is Increased in Lupus Nephritis. The sFas level
was slightly elevated in the LN subset with the G/G genotype
compared to SLE patients without LN (Figure 2).
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Table 1: Genotype and alleles frequencies of the −670A/G Fas polymorphism in SLE and LN patients and HS.
SLE (𝑛 = 43)
% (𝑛)
LN (𝑛 = 24)
% (𝑛)
HS (𝑛 = 54)
% (𝑛) 𝑃 value
Genotype
A/A 33 (14) 29 (7) 52 (28) §,&𝑃 = 0.22
A/G 30 (13) 38 (9) 22 (12)
G/G 37 (16) 33 (8) 26 (14)
Allele
A 48 (41) 48 (23) 63 (68)§ §,&𝑃 = 0.03∗
G 52 (45)& 52 (25) 37 (40) OR = 1.8695% CI = 1.007–3.45
A/A + A/G 63 (27) 67 (16) 74 (40)
GG 37 (16) 33 (8) 26 (14) 𝑃 = 0.23
AA 33 (14) 29 (7) 52 (28)Φ 𝑃 = 0.05∗
A/G + G/G 67 (29)𝜑 71 (17) 48 (26) OR = 2.2395% CI = 0.90–5.6
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Figure 1: Electrophoresis of PCR products in patients and controls.
The polymorphic fragments A/A resulted in a 232 bp band, the G/G
fragment resulted in a 188 bp band, and the A/G variation resulted


















Figure 2: The sFas concentration according to −670 Fas genotype
in LN and SLE patients and HS. The concentration of sFas was
increased in LN patients with the G/G genotype and was signifi-
cantly different from patients with SLE. ∗𝑃 < 0.05.
3.3. Association between sFas and the −670 Fas Polymorphism.
To address the question of whether sFas is associated with
the −670 polymorphism of the Fas receptor, the sFas levels in
the serum were compared between the A/A, A/G, and G/G














Figure 3: sFas concentration according to −670 Fas genotype. The
sFas concentrations in patients with the A/A and G/G genotypes
were not significantly different. In contrast, the sFas concentration
in patients with the A/G genotype was different compared to other
genotypes. ∗𝑃 < 0.05.
genotype was 668.99±344.04 𝜌g/mL, whereas the concentra-
tion for the A/G genotype was 1,140.17 ± 559.89 𝜌g/mL, and
this difference between genotypes was significant (𝑃 < 0.05).
In contrast, the G/G genotype showed a mean concentration
of 828.06±486.78 𝜌g/mL, and this value was not significantly
different compared to the A/A or A/G genotype (Figure 3).
3.4. sFas Is Increased and Correlated with Autoantibodies
and Proteinuria. The concentration of sFas was increased
regardless of the age of the SLE patients, with a mean value
of 845.84 ± 444.66 𝜌g/mL, whereas this concentration was
1, 342.997 ± 337.10 𝜌g/mL in LN subjects. When these values
were compared to those of the HS (630.44 ± 385.34 𝜌g/mL),
there was a significant difference (𝑃 < 0.001) (Figure 4).
3.5. Fas Protein and mRNA Is Expressed in Glomerulus. The
lupus nephritis biopsies included were 14 that had Class














Figure 4: The sFas level in the serum of SLE and LN patients and
HS. The concentration of sFas was increased in patients with LN.
∗∗
𝑃 < 0.01; ∗∗∗𝑃 < 001.
IV and 10 with Class III. Patients with Class IV nephritis
displayed the highest activity and chronicity scores, while
control kidneys had no histological evidence of renal disease
(Figures 5 and 6).
3.6. The Fas Protein Expression Was Increased in Lupus
Nephritis. The LN biopsies broadly expressed the Fas recep-
tor, whichwasmainly detected along the tubules, in glomeru-
lar endothelial cells and in the mesangium. Although HS
biopsies showed similar distributions of Fas, their staining
intensities were lower (Figure 7). Additionally, the color
intensity was measured by an image analyzer program, and
values were expressed as sum of intensities in pixels is one
hundred fields. Using this approach, significant differences of
Fas between HS and LN were observed (Figure 8).
3.7. Apoptotic Cell in Glomeruli. An increase in values
obtained by apoptotic cells in LN was observed, and signifi-
cant differences between HS and LN were observed (Figure 9
and Table 2).
Additionally, there was a significant difference between
the SLE and LN subsets (𝑃 < 0.01) (Figure 10). LN
subjects demonstrated a positive ANA test (90%) and a high
prevalence of anti-dsDNA antibodies (67%); this result was
in contrast with the SLE group without nephritis, which
showed an ANA level of 80% with anti-dsDNA antibodies
in only 7.14% of cases. Thus, we next sought to determine
whether sFas in LN is associated with a high prevalence
of autoantibodies, including anti-DNA antibodies, and pro-
teinuria. To this end, a Pearson’s correlation analysis was
performed, and as expected, a significant correlation among
proteinuria, podocyturia (as measured by WT-1), and the
levels of anti-dsDNAand anti-Ro-60 antibodieswas observed
in the LN subset. However, there was a lack of corre-
lation with anti-nRNP/Sm and anti-La-48 autoantibodies
(Table 3).
Table 2: Biomarkers in HS and lupus nephritis.
Group HS LN 𝑃 value
sFas 𝜌g/mL 630.44 ± 385.34 1,342.99 ± 337.10 0.001
mRNA Fas 13.73 ± 1.805 18.68 ± 0.915 0.006
Protein Fas 171.51 ± 8.468 221.53 ± 7.642 0.007
Apoptotic cells 23.496 ± 1.283 32.059 ± 5.800 0.01
sFas: soluble Fas, HS: healthy subjects, LN: lupus nephritis. Significance 𝑃 <
0.05.
4. Discussion
In the present investigation, the −670 polymorphism of the
promoter region of the Fas gene was analyzed. We also
sought to determine whether the association between LN and
sFas levels is associated with the −670 Fas polymorphism.
Finally, we evaluated whether these factors are associated
with the lupus nephritis susceptibility in theMexicanmestizo
population.
The present results suggest that the G allele of the Fas
promoter is associated with SLE susceptibility (OR, 1.86).
Second, an increased serum level of sFas was detected in
LN patients with the G/G and A/G −670 genotypes. Third,
this increase in sFas among LN patients with proteinuria
and podocyturia, suggests that the increase in the sFas level
may be transcriptionally regulated, and it is associated to the
G/G and A/G genotypes. Fourth, the broad expression of Fas
receptor in LN biopsies correlated with apoptotic features.
Associations between the A/G −670 Fas polymorphism
and autoimmune diseases, such as type 1 diabetes, multiple
sclerosis, Sjögren’s syndrome, rheumatoid arthritis (RA), and
SLE, have been described [19, 33, 34, 46]. Nevertheless, it
remains unclear how this polymorphism participates in LN
pathogenesis.
The present results suggest that the genotype and allelic
frequency of the G allele of the Fas −670 polymorphism are
associated with SLE in Mexican mestizo patients; therefore,
this genotype may confer susceptibility to SLE. We should
note that the studied population lives in the north-central
area of Mexico, and our results differ with those reported in
Japanese SLE patients in which the A allele was associated
with SLE development [43]. However, these results suggest
that the Fas promoter partially contributes to the pathogen-
esis of SLE [33]. Other studies in India have reported the
association between SLE and the −670 Fas polymorphism
[37], and the allelic differences with the present work seem
to be due to the mixed ethnic groups present in the Mexican
mestizo population [47].
Our results agree with other reports showing that the
−670 polymorphism is associated with certain ANA speci-
ficities, which is in agreement with a report on Korean SLE
patients [44]. Taking into account the fact that different
genes participate in SLE, transcriptional regulation of the Fas
receptor in SLE seems to be activated by IFN-𝛾 [43].
Regarding the possible association between the −670
polymorphism and sFas levels, we found that sFas levels were
increased in LN patients with the A/G and G/G genotypes,
which is in agreement with previous reports [33, 37, 43].
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(a) (b) (c)
(d) (e) (f)
Figure 5: The expression of mRNA Fas receptor in renal tissue of LN patients and HS by FISH. The upper panel (a), (b), and (c) shows the
HS tissue, and the lower panel (d), (e), and (f) shows a representative LN. (a) and (d) Expression of the mRNA Fas receptor (red). (b) and (e)
Staining in blue by DAPI. (c) and (f) show the overlapping (pink).
Table 3: Correlation between sFas levels and markers of disease in LN patients.
Proteinuria ≥ 0.5 g/L WT-1 anti-Ro-60 anti-dsDNA anti-MBG nRNP/Sm anti-La-48
sFas 𝑟 = 0.864 𝑟 = 0.718 𝑟 = 0.659 𝑟 = 0.593 𝑟 = 0.276 𝑟 = 0.522 𝑟 = −0.372
𝑃 = 0.01∗ 𝑃 = 0.004∗∗ 𝑃 = 0.05∗ 𝑃 = 0.032∗ 𝑃 = 0.440 𝑃 = 0.150 𝑃 = 0.324
∗Correlation is significant at the 0.05 level (two-tailed).
















Figure 6: Expression the mRNA Fas receptor in renal tissue of SLE,
LN patients, and HS. Difference between LN with other groups was
significant. ∗∗𝑃 < 0.006.
The meta-analysis studies related with Fas −670 A/G
polymorphism show that such genotype confers susceptibil-
ity to SLE in Asian population (Table 4) [33, 34]. We should
note that these studies do not include any Latin America
country; this is the first study on the Fas −670 polymorphism
in a population of north-central area ofMexico, as depicted in
Table 4, that compares our results with other reports [33, 34,
37, 40, 43, 44, 47].The studies on the association between Fas
−670 A/G polymorphism and SLE produced controversial
results; it may be because of the clinical heterogeneity,
different ethnicities, and real genetic heterogeneity. Another
possible explanation is the small sample size; nevertheless
our results agree with other reports showing the association
between the Fas −670 G allele carrier and SLE [33]. The
association of functional polymorphisms in the promoter
of Fas with SLE susceptibility has been a controversial
issue. Therefore different single-nucleotide polymorphisms
have been identified in the promoter region of Fas; one of
International Journal of Nephrology 7
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(d) (e) (f)
Figure 7: The expression of Fas receptor in renal tissue of LN patients and HS by IHC. Superior panel stained by H and E. Inferior panel,
















Figure 8: Expression of Fas receptor in renal tissue of LN patients
and HS. The expression of Fas was increased in patients with LN
(∗∗𝑃 < 0.007).
them is the substitution of A to G at position −670, which
theoretically affect the binding ability of the GAS binding
protein to the nuclear transcription element STAT-1; this
genotype decreases the promoter activity and consequently
the Fas-expression. Regarding the two forms of Fas receptor,
we should note that both normal Fas and the sFas transcripts
are derived by the same gene promoter; in the case of
sFas transcript it results from an alternative splicing that
truncates the transcript and results in a protein that lacks
intracellular and transmembrane domains (sFas). In theory
the increase of the sFas level might antagonize the Fas-FasL
apoptotic pathway [48]; nevertheless and taking into account
our results, the mRNA of Fas as well as the Fas protein
was fully expressed at glomerular level as our FISH and
immunohistochemistry assays demonstrated; furthermore
the Fas pathway was functional because we were able to
demonstrate correlation between Fas receptor expression and
apoptotic features of lupus nephritis patients as the TUNEL
assays demonstrated; another alternative explanation for sFas
increasing in LN patients could be secondary to the local
inflammatory process. In this scenario the matrix metallo-
proteinases (MMP) are produced and are related with renal
dysfunction; thereforeMMPassociates to proliferating events
at glomerular level, and therefore enhanced MMP activity in
lupus nephritis patients as well as in experimental models has
been reported [49], interestingly MMP can digest part of the
extracellular domain of Fas receptor [26] increasing the sFas
levels; it might be the case of our findings in lupus nephritis
patients, as we observed in patients with active renal disease,
and previously the association of high levels of sFas in patients
with kidney damage by lupus was reported [35, 50, 51].
Additionally, another study related with Fas −1377 poly-
morphism in SLE patients shows an increase in the rate of Fas
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(a) (b) (c)
Figure 9: TUNEL assays in renal tissue of LN patients and HS. Positive apoptotic cell exhibited nuclei tagged in green. (a) HS biopsies. (b)
and (c) show a representative of LN. The nuclei of nonapoptotic cell were red-tagged.
Table 4: Characteristics of the individual studies of the −670 (A/G) Fas polymorphism in SLE and sFAS adapted from [33, 34].







Hatef et al. [35] 2013 Iran 409.38/168
𝑃 = 0.03 32/46 ND ND
Moudi et al. [36] 2013 Iran ND 106/149 58/49 0.03
Pradhan [37] 2012 India 4771.5/1131.4
𝑃 = ND 70/70 58/42 0.001
Molin et al. [38] 2012 Germany ND 46/96 37/11.5 0.001
Man et al. [39] 2012 China ND 552/718 61.1/58.1 NS
Araste et al. [40] 2010 Iran 158.1/48.7
𝑃 = 0.001 249/212 51.6/49.5 NS
Sahebari et al. [25] 2010 Iran 372.2/190.3
𝑃 = 0.001 114/50 ND ND
Mahfoudh et al. [41] 2007 Tunisia 0/3,200 0/170 0/57 ND
Xu et al. [42] 2004 China ND 103/110 NS NS
Kanemitsu et al. [43] 2002 Japan ND 109/140 0.004
Lee et al. [44] 2001 Korea ND 87/86 NS NS
Al-Maini et al. [45] 2000 United Arab Emirates 600/260
𝑃 = 0.0001 39/22 ND ND
Huang et al. [19] 1997 Australia ND 79/86 NS NS
Jodo et al. [21] 1997 Japan 870/220
𝑃 = 0.001 77/40 ND ND
Present study 2014 Mexico 1094.41/630.44
𝑃 = 0.001 67/54 48/63 0.03
sFas: soluble Fas, SLE: systemic lupus erythematosus, ND: undetermined, NS: not significant.
transcription, which may increase the number of apoptotic
cells, resulting in a deficiency in the clearing of apoptotic
bodies. These cells undergo secondary necrosis, releasing
intracellular antigens that break down immune tolerance,
resulting in autoimmunity and tissue damage that affects
natural filters, such as the kidneys. In the present study, we
demonstrate that increased levels of sFas correlate with the
presence of autoantibodies and proteinuria due to podocyte
damage, and our results confirm previous reports [25].
Finally, we observed a higher sFas concentration in SLE
patients with greater proteinuria, reflecting podocyte damage
according to the increased levels of the urinary biomarker
WT-1. As a result, sFas may be used as an alternate biomarker
in patients with LN, as these levels may predict damage
to the ultrafiltration glomerular unit. In conclusion, the
present study indicates that the G allele of the Fas −670
polymorphism is associatedwith genetic susceptibility to SLE
as well as increased levels of sFas in patients with LN.
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Figure 10: TUNEL assays in renal tissue of LN patients and HS.The
intensity green belongs to glomerular apoptotic cells in LN biopsies,
the red color belongs to nonapoptotic cells. ∗∗𝑃 < 0.008.
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